SEC Company Response from Biodexa Pharmaceuticals Plc (BDRX) (CIK 0001643918) (BDRX) — Oct 20, 2015
Biodexa Pharmaceuticals Plc (BDRX) (CIK 0001643918)
Date: Oct. 20, 2015 · CIK: 0001643918 · Accession: 0001193125-15-348206
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-206305
Letter
Securities and Exchange Commission Division of Corporate Finance Attention: Johnny Gharib Re: Midatech Pharma PLC Registration Statement on Form F-4 (File No. 333-206305) Request for Acceleration of Effective Date
Dear Mr. Gharib:
Pursuant to Rule 461 of the General Rules and Regulations under the Act of 1933, as amended, Midatech Pharma PLC (the “Company”) hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form F-4 (as amended to date, the “Registration Statement”) and declare the Registration Statement effective as of 3:30 p.m., Eastern Time, on October 22, 2015, or as soon as practicable thereafter. The Company also requests the Commission to confirm such effective date and time in writing.
In connection with this request for acceleration, the Company acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceedings initiated by the Commission or any person under the federal securities laws of the United States.
[Signature Page Follows]
Very truly yours,
MIDATECH PHARMA PLC
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request October 20, 2015 BY EDGAR AND ELECTRONIC MAIL Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, DC 20549 Attention: Johnny Gharib Re: Midatech Pharma PLC Registration Statement on Form F-4 (File No. 333-206305) Request for Acceleration of Effective Date Dear Mr. Gharib: Pursuant to Rule 461 of the General Rules and Regulations under the Act of 1933, as amended, Midatech Pharma PLC (the “Company”) hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form F-4 (as amended to date, the “Registration Statement”) and declare the Registration Statement effective as of 3:30 p.m., Eastern Time, on October 22, 2015, or as soon as practicable thereafter. The Company also requests the Commission to confirm such effective date and time in writing. In connection with this request for acceleration, the Company acknowledges that: • should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceedings initiated by the Commission or any person under the federal securities laws of the United States. [Signature Page Follows] Very truly yours, MIDATECH PHARMA PLC By: /s/ Nicholas Robbins-Cherry Name: Title: Nicholas Robbins-Cherry Finance Director